Su Cheong Yeom

Prof. Su Cheong Yeom

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2022 in Science Advances
Verified
Journal Article
Open access
JHJeongpil Han
Jeongpil Han
MKMinJeong Kim
MinJeong Kim
BCBeom Seok Choi
Beom Seok Choi
JLJeong Hyeon Lee
Jeong Hyeon Lee
GLGeon Seong Lee
Geon Seong Lee
SYSu Cheong Yeom
Su Cheong Yeom
Hemophilia is a hereditary disease that remains incurable. Although innovative treatments such as gene therapy or bispecific antibody therapy have been introduced, substantial unmet needs still exist with respect to achieving long-lasting therapeutic effects and treatment options for inhibitor patients. Antithrombin (AT), an endogenous negative regulator of thrombin generation, is a potent genome editing target for sustainable treatment of patients with hemophilia A and B. In this study, we developed and optimized lipid nanoparticles (LNPs) to deliver Cas9 mRNA along with single guide RNA that targeted AT in the mouse liver. The LNP-mediated CRISPR-Cas9 delivery resulted in the inhibition of AT that led to improvement in thrombin generation. Bleeding-associated phenotypes were recovered in both hemophilia A and B mice. No active off-targets, liver-induced toxicity, and substantial anti-Cas9 immune responses were detected, indicating that the LNP-mediated CRISPR-Cas9 delivery was a safe and efficient approach for hemophilia therapy.

1 January 2021 in Immune Network
Verified
Journal Article
Open access
PDF file
SKSinae Kim
Sinae Kim
TNTam T. Nguyen
Tam T. Nguyen
ATAfeisha S. Taitt
Afeisha S. Taitt
HJHyunjhung Jhun
Hyunjhung Jhun
HPHo-Young Park
Ho-Young Park
SKSoohyun Kim
Soohyun Kim
Kim S, et al. Immune Netw. 2021 Dec;21(6):e38. https://doi.org/10.4110/in.2021.21.e38

6 April 2018 in Experimental & Molecular Medicine
Verified
Journal Article
Open access
PDF file
DJDa Eun Jang
Da Eun Jang
JLJae Young Lee
Jae Young Lee
JLJae Hoon Lee
Jae Hoon Lee
OKOk Jae Koo
Ok Jae Koo
HBHee Sook Bae
Hee Sook Bae
SYSu Cheong Yeom
Su Cheong Yeom
The CRISPR/Cas9 system is widely applied in genome engineering due to its simplicity and versatility. Although this has revolutionized genome-editing technology, knockin animal generation via homology directed repair (HDR) is not as efficient as nonhomologous end-joining DNA-repair-dependent knockout. Although its double-strand break activity may vary, Cas9 derived from Streptococcus pyogenens allows robust design of single-guide RNAs (sgRNAs) within the target sequence; However, prescreening for different sgRNA activities delays the process of transgenic animal generation. To overcome this limitation, multiple sets of different sgRNAs were examined for their knockin efficiency. We discovered profound advantages associated with single-stranded oligo-donor-mediated HDR processes using overlapping sgRNAs (sharing at least five base pairs of the target sites) as compared with using non-overlapping sgRNAs for knock-in mouse generation. Studies utilizing cell lines revealed shorter sequence deletions near target mutations using overlapping sgRNAs as compared with those observed using non-overlapping sgRNAs, which may favor the HDR process. Using this simple method, we successfully generated several transgenic mouse lines harboring loxP insertions or single-nucleotide substitutions with a highly efficiency of 18–38%. Our results demonstrate a simple and efficient method for generating transgenic animals harboring foreign-sequence knockins or short-nucleotide substitutions by the use of overlapping sgRNAs.

21 March 2023 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
JLJeong Hyeon Lee
Jeong Hyeon Lee
JHJeong Pil Han
Jeong Pil Han
DSDong Woo Song
Dong Woo Song
GLGeon Seong Lee
Geon Seong Lee
BCBeom Seok Choi
Beom Seok Choi
SYSu Cheong Yeom
Su Cheong Yeom
Recent therapeutic strategies for hemophilia include long-term therapeutic gene expression using adeno-associated virus (AAV) and rebalancing therapy via the downregulation of anticoagulant pathways. However, these approaches have limitations in immune responses or insufficiency to control acute bleeding. Thus, we developed a therapeutic strategy for hemophilia B by a combined rebalancing and human factor 9 (hF9) gene knockin (KI) using a lipid nanoparticle (LNP) and AAV. Antithrombin (AT; Serpin Family C Member 1 [Serpinc1]) was selected as the target anticoagulation pathway for the gene KI. First, the combined use of LNP-clustered regularly interspaced short palindromic repeats (CRISPR) and AAV donor resulted in 20% insertions or deletions (indels) in Serpinc1 and 67% reduction of blood mouse AT concentration. Second, hF9 coding sequences were integrated into approximately 3% of the target locus. hF9 KI yielded approximately 1,000 ng/mL human factor IX (hFIX) and restored coagulation activity to a normal level. LNP-CRISPR injection caused sustained AT downregulation and hFIX production up to 63 weeks. AT inhibition and hFIX protein-production ability could be maintained by the proliferation of genetically edited hepatocytes in the case of partial hepatectomy. The co-administration of AAV and LNP showed no severe side effects except random integrations. Our results demonstrate hemophilia B therapy by a combination of rebalancing and hF9 KI using LNP and AAV.

20 July 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
SPSeung Yong Park
Seung Yong Park
YHYasmin Hisham
Yasmin Hisham
HSHyun Mu Shin
Hyun Mu Shin
SYSu Cheong Yeom
Su Cheong Yeom
SKSoohyun Kim
Soohyun Kim
Natural soluble antagonist and decoy receptor on the surface of the cell membrane are evolving as crucial immune system regulators as these molecules are capable of recognizing, binding, and neutralizing (so-called inhibitors) their targeted ligands. Eventually, these soluble antagonists and decoy receptors terminate signaling by prohibiting ligands from connecting to their receptors on the surface of cell membrane. Interleukin-18 binding protein (IL-18BP) participates in regulating both Th1 and Th2 cytokines. IL-18BP is a soluble neutralizing protein belonging to the immunoglobulin (Ig) superfamily as it harbors a single Ig domain. The Ig domain is essential for its binding to the IL-18 ligand and holds partial homology to the IL-1 receptor 2 (IL-1R2) known as a decoy receptor of IL-1α and IL-1β. IL-18BP was defined as a unique soluble IL-18BP that is distinct from IL-18Rα and IL-18Rβ chain. IL-18BP is encoded by a separated gene, contains 8 exons, and is located at chr.11 q13.4 within the human genome. In this review, we address the difference in the biological activity of IL-18BP isoforms, in the immunity balancing Th1 and Th2 immune response, its critical role in autoimmune diseases, as well as current clinical trials of recombinant IL-18BP (rIL-18BP) or equivalent.

1 March 2023 in Food Research International
Verified
Journal Article
Closed access
HYHye Ree Yoon
Hye Ree Yoon
SHSuk Han
Suk Han
SSSeung Chul Shin
Seung Chul Shin
SYSu Cheong Yeom
Su Cheong Yeom
HKHyo Jin Kim
Hyo Jin Kim